Contemporary OB/GYN week in review: RSV, elinzanetant, and more
Review some of the top stories from the Contemporary OB/GYN website over the last week, and catch up on anything you may have missed.
Contemporary OB/GYN week in review: RSV, elinzanetant, and more
Thank you for visiting the Contemporary OB/GYN® website. Take a look at some of our top stories from last week (Monday, January 8 - Friday, January 12, 2023), and click each link to read and watch anything you may have missed.
1.) RSV this year: Clinician insights and urgent vaccination strategies
In a recent panel, clinicians discussed rising cases of respiratory syncytial virus (RSV), vaccination challenges, and the urgent need for public awareness and intervention strategies in the 2023 to 2024 season.
Click here for the full article.
2.) Elinzanetant shows safety, efficacy for management of vasomotor symptoms
Elinzanetant demonstrated positive safety and efficacy data in managing menopausal vasomotor symptoms, highlighting its potential as a treatment for improving women's quality of life during menopause.
Click here for the full article.
3.) Link revealed between infertility and midlife cardiovascular health
A recent study highlights how a history of infertility may signal decreased cardiovascular health in midlife, emphasizing the need for comprehensive risk assessments in female patients.
Click here for the full article.
4.) LACC trial sparks surge in open abdominal hysterectomy for cervical cancer
A recent study revealed a substantial rise in open abdominal hysterectomy following the Laparoscopic Approach to Cervical Cancer trial, impacting surgical approaches but not 30-day complications.
Click here for the full article.
5.) Disparities in maternal health linked to severe maternal morbidity
A recent study revealed that Black women, especially those facing extended travel distances for maternity care, are at a heightened risk of severe maternal morbidity, shedding light on needs for equitable maternal care policies in the United States.
Severe maternal morbidity linked to mental health risks post-delivery
April 26th 2024A recent study revealed that severe maternal morbidity during pregnancy increases the likelihood of mental health hospitalizations or emergency department visits up to 13 years post-delivery, emphasizing the need for mental health screening.
Read More
S4E3: Myfembree for moderate-to-severe endometriosis pain: Potential for adolescents
March 2nd 2022In this episode of Pap Talk, Contemporary OB/GYN® Associate Editor Lindsey Carr sat down with Jessica Shim, MD, an attending at in the Division of Gynecology, Department of Surgery, Boston Children’s Hospital; Harvard Medical School Boston, Massachusetts, to discuss Myfembree (relugolix, estradiol, and norethindrone acetate tablets; Myovant Sciences, Pfizer) and its possible approval in May 2022.
Listen
FDA approves updated label for Biktarvy against HIV-1
April 26th 2024Gilead Sciences has announced FDA approval of an updated Biktarvy label, showcasing safety and efficacy data from a phase 1b trial, positioning it as a pivotal treatment option for pregnant individuals with HIV-1 and suppressed viral load.
Read More
S4E1: New RNA platform can predict pregnancy complications
February 11th 2022In this episode of Pap Talk, Contemporary OB/GYN® sat down with Maneesh Jain, CEO of Mirvie, and Michal Elovitz, MD, chief medical advisor at Mirvie, a new RNA platform that is able to predict pregnancy complications by revealing the biology of each pregnancy. They discussed recently published data regarding the platform's ability to predict preeclampsia and preterm birth.
Listen
SART data indicates rise in IVF use in 2022
April 24th 2024Dive into the latest statistics from the Society for Assisted Reproductive Technology, revealing a 6% increase in in vitro fertilization cycles and a surge in egg freezing, amidst a landscape of rising fertility service demand and evolving clinical practices.
Read More
